Switch theme
Sign up to access all valuation multiples
Curasight AS is a clinical-stage biotech company committed to improving both diagnosis and the treatment of certain types of cancer. The company is focused on exploiting Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor.
2013
4
LTM Revenue n/a
LTM EBITDA -$5.8M
$15.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Curasight has a last 12-month revenue of n/a and a last 12-month EBITDA of -$5.8M.
In the most recent fiscal year, Curasight achieved revenue of n/a and an EBITDA of -$5.7M.
Curasight expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Curasight valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | -$1.7M | -$3.7M | XXX | XXX | XXX |
| Gross Margin | NaN% | -Infinity% | XXX | XXX | XXX |
| EBITDA | -$4.6M | -$5.7M | XXX | XXX | XXX |
| EBITDA Margin | NaN% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$2.6M | -$3.8M | XXX | XXX | XXX |
| Net Margin | NaN% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Curasight's stock price is DKK 6 (or $1).
Curasight has current market cap of DKK 116M (or $16.7M), and EV of DKK 106M (or $15.3M).
See Curasight trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15.3M | $16.7M | XXX | XXX | XXX | XXX | $-0.25 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Curasight has market cap of $16.7M and EV of $15.3M.
Curasight's trades at n/a LTM EV/Revenue multiple, and -2.6x LTM EBITDA.
Analysts estimate Curasight's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Curasight and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $15.3M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -2.7x | XXX | XXX | XXX |
| P/E | -3.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -3.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCurasight's NTM/LTM revenue growth is n/a
Curasight's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Curasight's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Curasight's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Curasight and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Curasight acquired XXX companies to date.
Last acquisition by Curasight was XXXXXXXX, XXXXX XXXXX XXXXXX . Curasight acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Curasight founded? | Curasight was founded in 2013. |
| Where is Curasight headquartered? | Curasight is headquartered in Sweden. |
| How many employees does Curasight have? | As of today, Curasight has 4 employees. |
| Is Curasight publicy listed? | Yes, Curasight is a public company listed on SAT. |
| What is the stock symbol of Curasight? | Curasight trades under CURAS ticker. |
| When did Curasight go public? | Curasight went public in 2020. |
| Who are competitors of Curasight? | Similar companies to Curasight include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Curasight? | Curasight's current market cap is $16.7M |
| What is the current EBITDA of Curasight? | Curasight's last 12-month EBITDA is -$5.8M. |
| What is the current EV/EBITDA multiple of Curasight? | Current EBITDA multiple of Curasight is -2.6x. |
| Is Curasight profitable? | Yes, Curasight is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
